Telitacicept Pre-filled

Phase 1Small molecule

TTongji Hospital

Telitacicept Pre-filled is one of 2 small molecule programs targeting Telitacicept. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TelitaciceptRecruiting

TelitaciceptPhase 1

Recruiting

Competition

Competitive Landscape

1 competitor in Telitacicept

#DrugCompanyPhaseTrials

Telitacicept

VVor Biopharma

Phase 3

6 2

Telitacicept Pre-filled

TTongji Hospital

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Post-ApprovalRecruiting

Interstitial Lung Disease

NCT07077486

Clinical

Trials by Indication[1]

Interstitial Lung Disease1 trial

Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease

Recruiting·TTongji Hospital·Phase 4·NCT07077486·100 enrolled

Telitacicept1 trial

A Single Dose Study to Investigate the Pharmacokinetics (PK) of Telitacicept Pre-filled Injection and Freeze-dried Powder Injection in Chinese Healthy Subjects

Recruiting·RRemeGen Co., Ltd.·Phase 1·NCT06549959·248 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Telitacicept Pre-filled. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Telitacicept Pre-filled compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Telitacicept Pre-filled. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tongji Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: TTongji Hospital

Telitacicept Pre-filled

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Interstitial Lung Disease1 trial

Telitacicept1 trial

References

Drug Info

Quick Facts

Related News